Lasma LC Kid Tablet contains Levocetirizine 2.5 mg and Montelukast 4 mg, formulated for pediatric use to manage allergic conditions effectively. Levocetirizine is a third-generation non-sedating antihistamine that selectively inhibits peripheral H1 receptors, thereby reducing symptoms such as sneezing, rhinorrhea, itching, and urticaria associated with allergic rhinitis and chronic urticaria. Montelukast is a leukotriene receptor antagonist that blocks the cysteinyl leukotriene D4 receptor, contributing to the prevention and control of asthma symptoms and allergic rhinitis by reducing airway inflammation and bronchoconstriction. The combination of these two agents provides a dual mechanism of action, targeting both histamine-mediated allergic reactions and leukotriene-mediated inflammatory pathways, enhancing symptom control in pediatric patients with allergic rhinitis, asthma, or concurrent allergic conditions. Lasma LC Kid is indicated for children requiring symptomatic relief from seasonal or perennial allergic rhinitis and mild to moderate asthma. It is generally well tolerated, with a favorable safety profile when used as directed. Dosage and administration should be based on the pediatrician’s recommendation, considering the child’s age, weight, and clinical condition. This combination therapy offers an effective option for improving quality of life in children suffering from allergic respiratory disorders.